Lodelcizumab, a newly discovered monoclonal antibody, represents a potentially solution in the effort against severe migraines. Unlike many current therapies that focus pain itself, lodelcizumab uniquely reduces CGRP, https://jonasducf346863.pointblog.net/lodelcizumab-a-innovative-strategy-to-cephalalgia-therapy-94944232